SAN FRANCISCO, Sept. 17, 2018 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a commercial-stage
biopharmaceutical company focused on saving and improving the lives
of pets, will present at the Cantor Global Healthcare Conference on
October 1 and the Ladenburg Thalmann
2018 Healthcare Conference on October 2,
2018 in New York City.
Denise Bevers, Co-Founder and
Chief Operating Officer, will present and be available for
one-on-one meetings. During this time, investors will have the
opportunity to discuss recent developments, including the launch of
KindredBio's first product, key therapeutic programs in
development, and upcoming milestones.
Presentation Details:
Cantor Global Healthcare Conference
Date: Monday, October 1, 2018
Time: 1:45-2:15 PM ET
Location: InterContinental New York Barclay Hotel, Track 5 -
Grand Ballroom 2
Webcast URL: Click here
Ladenburg Thalmann 2018 Healthcare Conference
Date: Tuesday, October 2, 2018
Time: 3:00-3:25 PM ET
Location: Sofitel New York, Track 4 - St. Germain III
Webcast URL: Click here
An archived version of the above webcasts will be available for
30 days on the Company's website.
Important Safety Information
Mirataz® (mirtazapine
transdermal ointment) is for topical use in cats only under
veterinary supervision. Do not use in cats with a known
hypersensitivity to mirtazapine or any of the excipients or in cats
treated with monoamine oxidase inhibitors (MAOIs). Not for human
use. Keep out of reach of children. Wear gloves to apply and wash
hands after. Avoid contact with treated cat for 2 hours following
application. The most common adverse reactions include
application site reactions, behavioral abnormalities (vocalization
and hyperactivity) and vomiting. Please see the full Prescribing
Information.
About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company
focused on saving and improving the lives of pets. Its mission is
to bring to pets the same kinds of safe and effective medicines
that human family members enjoy. The Company's strategy is to
identify compounds and targets that have already demonstrated
safety and efficacy in humans and to develop therapeutics based on
these validated compounds and targets for dogs, cats and horses.
The Company has a deep pipeline of novel drugs and biologics in
development across many therapeutic classes. KindredBio's first
approved drug is Mirataz® (mirtazapine transdermal ointment) for
the management of weight loss in cats.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with KindredBio
on Facebook at www.Facebook.com/KindredBio.
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-cantor-global-healthcare-conference-and-ladenburg-thalmann-2018-healthcare-conference-300713183.html
SOURCE Kindred Biosciences, Inc.